ArticleBMC health services research2022

Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries.

Hyun Kyeong Yoo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.